Durie, Ian A.
Tehrani, Zahra R. https://orcid.org/0000-0002-1127-1290
Karaaslan, Elif
Sorvillo, Teresa E. https://orcid.org/0000-0003-2943-4040
McGuire, Jack
Golden, Joseph W. https://orcid.org/0000-0002-9709-313X
Welch, Stephen R. https://orcid.org/0000-0002-6905-8521
Kainulainen, Markus H. https://orcid.org/0000-0003-2492-1210
Harmon, Jessica R. https://orcid.org/0000-0001-6051-0254
Mousa, Jarrod J. https://orcid.org/0000-0003-4709-2478
Gonzalez, David
Enos, Suzanne
Koksal, Iftihar
Yilmaz, Gurdal
Karakoc, Hanife Nur
Hamidi, Sanaz
Albay, Cansu
Spengler, Jessica R. https://orcid.org/0000-0002-5383-0513
Spiropoulou, Christina F.
Garrison, Aura R. https://orcid.org/0000-0003-3034-6400
Sajadi, Mohammad M.
Bergeron, Éric https://orcid.org/0000-0003-3398-8628
Pegan, Scott D. https://orcid.org/0000-0002-2958-5319
Funding for this research was provided by:
Military Infectious Disease Research Program
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI151006, R01AI151006-03S1, R01AI151006)
United States Department of Defense | Defense Threat Reduction Agency (HDTRA12210007, HDTRA12210007)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 1 July 2022
Accepted: 10 November 2022
First Online: 26 November 2022
Competing interests
: A.R.G. and J.W.G. are inventors on a patent application related to the use of mAb 13G8 as a therapeutic, PCT/US2020/012621. The remaining authors declare no competing interests.